With this model, researchers may be able to discover antibody drugs capable of targeting a wide range of infectious diseases.

Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups ...

In this article, we present a framework designed to evaluate the progress and impact of AI tools across various use cases in drug discovery ... is gaining momentum in antibody drug design ...

Jan. 13, 2025 (GLOBE NEWSWIRE) -- InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize drug discovery and .

Absci's advanced de novo antibody design models will benefit from AMD's optimized AI solutions, potentially leading to reduced infrastructure costs and faster innovation cycles in drug discovery.

Absci Corporation (ABSI), a Washington-based biotechnology company, Wednesday has announced a strategic collaboration with AMD to ...

ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) today announced the launch of its AI-powered pipeline of both optimized and new therapeutics, a system set ...

Absci Corporation and Owkin have announced a partnership to combine their advanced AI platforms for the rapid discovery ... AI Drug Creation platform, including its de novo antibody design models ...

Chip maker AMD is investing $20 million in AI drug startup Absci, which will use AMD chips and software for drug development.

GUILFORD, Conn., Jan. 13, 2025 (GLOBE NEWSWIRE) -- InveniAI LLC, a global leader in the application of artificial intelligence (AI), machine learning (ML), and generative AI tools to revolutionize ...

"By harnessing AI and rethinking drug discovery from the ground up, we are not just improving the process—we are fundamentally changing what’s possible. This pipeline lays the foundation for ...